Cristi King

Application of pharmacogenomics in the individualization of chemotherapy for gastrointestinal malignancies.

Distribution of ITPA P32T alleles in multiple world populations.

ABCG2 pharmacogenetics: ethnic differences in allele frequency and assessment of influence on irinotecan disposition.

Pyrosequencing of clinically relevant polymorphisms.

Disposition of 9-nitrocamptothecin and its 9-aminocamptothecin metabolite in relation to ABC transporter genotypes.

ABCB1 2677G>T/A genotype and paclitaxel pharmacogenetics in ovarian cancer.

Pyrosequencing: a simple method for accurate genotyping.

Identification of NR1I2 genetic variation using resequencing.

Pharmacogenetic assessment of toxicity and outcome after platinum plus taxane chemotherapy in ovarian cancer: the Scottish Randomised Trial in Ovarian Cancer.

CYP4F2 genetic variant alters required warfarin dose.

Performance of commercial platforms for rapid genotyping of polymorphisms affecting warfarin dose.

Pharmacogenetic predictors of adverse events and response to chemotherapy in metastatic colorectal cancer: results from North American Gastrointestinal Intergroup Trial N9741.

Gamma-glutamyl carboxylase and its influence on warfarin dose.